NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.

Christina I Tsien,Stephanie L Pugh,Adam P Dicker,Jeffrey J Raizer,Martha M Matuszak,Enrico C Lallana,Jiayi Huang,Ozer Algan,Nimisha Deb,Lorraine Portelance,John L Villano,John T Hamm,Kevin S Oh,Arif N Ali,Michelle M Kim,Scott M Lindhorst,Minesh P Mehta

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 40|浏览81

暂无评分

摘要

To our knowledge, NRG Oncology/RTOG1205 is the first prospective, randomized multi-institutional study to evaluate the safety and efficacy of re-RT in recurrent GBM using modern RT techniques. Overall, re-RT was shown to be safe and well tolerated. BEV + RT demonstrated a clinically meaningful improvement in PFS, specifically the 6-month PFS rate but no difference in OS.

查看译文

关键词

recurrent glioblastoma,reirradiation versus bevacizumab alone,concurrent bevacizumab,oncology/rtog1205,randomized phase ii trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要